Get the Stockscreener App
0.95
1.05%
-0.0101
After Hours:
.95
Kronos Bio Inc stock is traded at $0.95, with a volume of 421.42K.
It is down -1.05% in the last 24 hours and down -3.16% over the past month.
Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine plan by targeting dysregulated transcription. The company operates in one business segment, the development of biopharmaceutical products.
See More
Previous Close:
$0.9601
Open:
$1
24h Volume:
421.42K
Relative Volume:
3.09
Market Cap:
$57.32M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.4502
EPS:
-2.11
Net Cash Flow:
$-79.26M
1W Performance:
+5.20%
1M Performance:
-3.16%
6M Performance:
+19.50%
1Y Performance:
-19.49%
1-Day Range:
$0.9353
$1.00
1-Week Range:
$0.842
$1.00
52-Week Range:
$0.69
$1.60
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
(650) 781-5200
Address
1300 S. EL CAMINO REAL, SAN MATEO
Compare KRON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KRON
Kronos Bio Inc
|
0.95 | 57.32M | 0 | -112.67M | -79.26M | -1.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-14-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Nov-14-24 | Downgrade | TD Cowen | Buy → Hold |
| Sep-14-22 | Initiated | Berenberg | Buy |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jun-24-21 | Initiated | H.C. Wainwright | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Goldman | Buy |
| Nov-03-20 | Initiated | Jefferies | Buy |
| Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
A Look At The Behavior Of Kronos Bio Inc (KRON) Stock - Stocks Register
Kronos Bio announces interim CEO and workforce cuts of 83% - Yahoo Finance
Kronos Bio Stock Jumps After Deep Workforce Cuts And CEO Shuffle: Retail Aligns With Shake-Up - MSN
Strategic shift at Kronos creates CEO vacancy - The Pharma Letter
Kronos Bio to lay off 83% of staff as CEO steps downSan Francisco Business Times - The Business Journals
Kronos Bio announces layoffs and executive changes By Investing.com - Investing.com Nigeria
Kronos Bio, Inc. Announces Management Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio, Inc. Announces CEO Changes, Effective December 3, 2024 - Marketscreener.com
Kronos Bio Shakes Up LeadershipCuts 83% Of Workforce Amid Strategic Overhaul - AOL
Biotech with Cambridge lab slashes 83% of staff, CEO departs - The Business Journals
Kronos Bio announces layoffs and executive changes - Investing.com India
Kronos Bio stock in focus on CEO change, layoffs (KRON:NASDAQ) - Seeking Alpha
Kronos Bio to Cut 83% Of Workforce, Names Interim CEO - MarketWatch
Kronos Bio Announces CEO Transition and Reduction in Force - GlobeNewswire
Kronos Bio Cuts 83% of Workforce, Names New CEO Amid Strategic Review | KRON Stock News - StockTitan
Kronos Bio Restructures Workforce and Leadership - TipRanks
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Kronos, Idorsia plan layoffs; PTC shelves ALS drug - Yahoo Finance
KRON (Kronos Bio) Cash Flow from Discontinued Operations : $0.00 Mil (TTM As of Sep. 2024) - GuruFocus.com
Petri Dish: Kronos Bio seeks merger; Former Biogen R&D head joins investment firm - The Business Journals
Kronos Bio downgraded by Piper Sandler, TD Cowen - MSN
Kronos Bio Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Kronos Bio Provides Update on Review of Strategic Alternatives - Marketscreener.com
Kronos Bio shares downgraded to hold by TD Cowen - Investing.com Australia
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024 - The Manila Times
Kronos Bio Highlights Preclinical Data that Show p300 KAT - GlobeNewswire
Kronos Bio's KB-7898 Shows 50% Reduction in Inflammation Markers in Preclinical Study | KRON Stock News - StockTitan
Kronos Bio stock takes a hit with piper sandler slashing price target - Investing.com
Kronos mulls ‘strategic alternatives’ after axing cancer drug development - Pharmaceutical Technology
Kronos Bio (NASDAQ:KRON) Rating Lowered to "Hold" at TD Cowen - MarketBeat
Kronos Bio downgraded by Piper Sandler, TD Cowen (NASDAQ:KRON) - Seeking Alpha
Kronos Bio (NASDAQ:KRON) Stock Rating Lowered by Piper Sandler - MarketBeat
Kronos Bio earnings beat by $0.05, revenue topped estimates - Investing.com UK
Kronos Bio, Inc. (KRON) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives - The Manila Times
Kronos Bio Reports Third Quarter 2024 Financial Results and - GlobeNewswire
Kronos Bio Halts Cancer Drug Trial, Explores Strategic Alternatives Amid Safety Concerns | KRON Stock News - StockTitan
Kronos Bio's Market Cap Drops To US$50m Leaving Insiders With Losses - Simply Wall St
Kronos Bio faces Nasdaq delisting over share price - Investing.com India
Kronos Bio faces Nasdaq delisting over share price By Investing.com - Investing.com UK
Kronos Bio to Present Data at the ASH Annual Meeting from p300 KAT Inhibition Program in Multiple Myeloma - GlobeNewswire
Kronos Bio to Present Breakthrough Multiple Myeloma Treatment Data at ASH 2024 | KRON Stock News - StockTitan
Non-Hodgkin’s Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
Kronos Bio, Inc. (NASDAQ:KRON) Sees Large Decline in Short Interest - Defense World
Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace
Non-Hodgkin Lymphoma Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers - The Globe and Mail
Nio Inc ADR (NIO-N) QuotePress Release - The Globe and Mail
Phillips-Van Heusen Corp (PVH-N) QuotePress Release - The Globe and Mail
After Plunging -23.49% in 4 Weeks, Here's Why the Trend Might Reverse for Kronos Bio (KRON) - MSN
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors - The Manila Times
Kronos Bio Inc Stock (KRON) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):